<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655992</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2012-09 CBCSG010</org_study_id>
    <nct_id>NCT01655992</nct_id>
  </id_info>
  <brief_title>A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)</brief_title>
  <official_title>A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing S1 generic With Capecitabine in Patients With Metastatic Breast Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing S1 generic(Tegafur，Gimeracil and Oteracil Potassium Capsules) With Capecitabine in
      Patients With Metastatic Breast Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>1.5 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>S1 generic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg／m2 bid four weeks on two weeks off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2500mg／m2／day divided into twice two weeks on one week off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>2500mg／m2／day divided into twice two weeks on one week off</description>
    <arm_group_label>capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1 generic</intervention_name>
    <description>40mg／m2 bid four weeks on two weeks off</description>
    <arm_group_label>S1 generic</arm_group_label>
    <other_name>Tegafur，Gimeracil and Oteracil Potassium Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer

          -  Pretreated metastatic breast cancer not more than 2 lines chemotherapy

          -  Have not been previously treated with capecitabine,oral fluracil

          -  ECOG performance status of ≤ 1

          -  Be female and ≥ 18 and ≤ 75 years of age

          -  Have at least one target lesion according to the RECIST criteria 1.1

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  ECOG ≥ 2

          -  Have been treated with capecitabine

          -  Evidence of CNS metastasis

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast
             cancer

          -  Abnormal laboratory values: hemoglobin &lt; 10.0 g/dl, absolute neutrophil count &lt;
             1.5×10^9/L, platelet count &lt; 100×10^9/L, serum creatinine &gt; upper limit of normal
             (ULN), serum bilirubin &gt; ULN, ALT and AST &gt; 5×ULN, AKP &gt; 5×ULN

          -  Serious uncontrolled intercurrent infection

          -  Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi-chun Hu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Univeristy Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Vice Director of department of medical oncology</investigator_title>
  </responsible_party>
  <keyword>capecitabine</keyword>
  <keyword>Tegafur，Gimeracil and Oteracil Potassium Capsules</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
